These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 25702976)
21. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Prebet T; Fenaux P; Vey N; Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503 [No Abstract] [Full Text] [Related]
22. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Estey EH Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301 [TBL] [Abstract][Full Text] [Related]
23. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809 [TBL] [Abstract][Full Text] [Related]
24. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Loiseau C; Ali A; Itzykson R Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365 [TBL] [Abstract][Full Text] [Related]
25. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Roberts DA; Steensma DP Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600 [TBL] [Abstract][Full Text] [Related]
26. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075 [TBL] [Abstract][Full Text] [Related]
27. Targeting DNA methylation. Issa JP; Kantarjian HM Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174 [TBL] [Abstract][Full Text] [Related]
28. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Xie M; Jiang Q; Xie Y Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977 [TBL] [Abstract][Full Text] [Related]
29. Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents. Odenike O Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):460-469. PubMed ID: 29222294 [TBL] [Abstract][Full Text] [Related]
30. Azacitidine-Induced Pericarditis: A Case Series. Newman M; Malla M; Gojo I Pharmacotherapy; 2016 Apr; 36(4):443-8. PubMed ID: 26940554 [TBL] [Abstract][Full Text] [Related]
31. Decitabine. Daskalakis M; Blagitko-Dorfs N; Hackanson B Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836 [TBL] [Abstract][Full Text] [Related]
32. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975 [TBL] [Abstract][Full Text] [Related]
33. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108 [TBL] [Abstract][Full Text] [Related]
34. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]. Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776 [No Abstract] [Full Text] [Related]
35. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. Jung HA; Maeng CH; Kim M; Kim S; Jung CW; Jang JH Oncotarget; 2015 Jun; 6(18):16653-62. PubMed ID: 25938546 [TBL] [Abstract][Full Text] [Related]
36. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745 [TBL] [Abstract][Full Text] [Related]
37. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia. Flotho C; Sommer S; Lübbert M Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488 [TBL] [Abstract][Full Text] [Related]
38. Use of hypomethylating agents in myelodysplastic syndromes. Atallah E; Garcia-Manero G Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928 [TBL] [Abstract][Full Text] [Related]
39. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370 [No Abstract] [Full Text] [Related]
40. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]